Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

Researchers found a significant reduction in the risk for a first-time AD diagnosis in association with semaglutide.

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time in people with ...

Dr. Whit Roberts of Health Utah says he is concerned about the financial costs and health risks potentially posed by popular ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

In a groundbreaking new study, the active ingredient in Ozempic was found to be so effective at treating arthritis that ...

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Trying to lose weight quickly can feel like an uphill battle, but weight loss medications like Ozempic or Wegovy can speed up ...